🚀 VC round data is live in beta, check it out!
Ypsomed Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ypsomed and similar public comparables like Snibe, Andon Health, APT Medical, Imeik Technology Development and more.
Ypsomed Overview
About Ypsomed
Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a click-on function. The company operates under two reportable segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care.
Founded
2003
HQ
Employees
2.8K
Website
Financials (LTM)
EV
$5B
Ypsomed Financials
Ypsomed reported last 12-month revenue of $924M and EBITDA of $421M.
In the same LTM period, Ypsomed generated $410M in gross profit, $421M in EBITDA, and $261M in net income.
Revenue (LTM)
Ypsomed P&L
In the most recent fiscal year, Ypsomed reported revenue of $958M and EBITDA of $254M.
Ypsomed expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $924M | XXX | $958M | XXX | XXX | XXX |
| Gross Profit | $410M | XXX | $374M | XXX | XXX | XXX |
| Gross Margin | 44% | XXX | 39% | XXX | XXX | XXX |
| EBITDA | $421M | XXX | $254M | XXX | XXX | XXX |
| EBITDA Margin | 46% | XXX | 27% | XXX | XXX | XXX |
| EBIT Margin | 32% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $261M | XXX | $112M | XXX | XXX | XXX |
| Net Margin | 28% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | — | — | $295M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Ypsomed Stock Performance
Ypsomed has current market cap of $5B, and enterprise value of $5B.
Market Cap Evolution
Ypsomed's stock price is $380.65.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $5B | 0.2% | XXX | XXX | XXX | $8.21 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialYpsomed Valuation Multiples
Ypsomed trades at 5.9x EV/Revenue multiple, and 13.1x EV/EBITDA.
EV / Revenue (LTM)
Ypsomed Financial Valuation Multiples
As of April 20, 2026, Ypsomed has market cap of $5B and EV of $5B.
Equity research analysts estimate Ypsomed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ypsomed has a P/E ratio of 19.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV/Revenue | 5.9x | XXX | 5.7x | XXX | XXX | XXX |
| EV/EBITDA | 13.1x | XXX | 21.6x | XXX | XXX | XXX |
| EV/EBIT | 18.5x | XXX | 38.0x | XXX | XXX | XXX |
| EV/Gross Profit | 13.4x | XXX | 14.7x | XXX | XXX | XXX |
| P/E | 19.9x | XXX | 46.4x | XXX | XXX | XXX |
| EV/FCF | 172.6x | XXX | (35.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ypsomed Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Ypsomed Margins & Growth Rates
Ypsomed's revenue in the last 12 month declined by (1%).
Ypsomed's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Ypsomed's rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ypsomed's rule of X is 40% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Ypsomed Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (1%) | XXX | (4%) | XXX | XXX | XXX |
| EBITDA Margin | 46% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | (0%) | XXX | 65% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 8% | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 24% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Ypsomed Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Ypsomed | XXX | XXX | XXX | XXX | XXX | XXX |
| Snibe | XXX | XXX | XXX | XXX | XXX | XXX |
| Andon Health | XXX | XXX | XXX | XXX | XXX | XXX |
| APT Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Imeik Technology Development | XXX | XXX | XXX | XXX | XXX | XXX |
| Mirion | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ypsomed M&A Activity
Ypsomed acquired XXX companies to date.
Last acquisition by Ypsomed was on XXXXXXXX, XXXXX. Ypsomed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Ypsomed
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialYpsomed Investment Activity
Ypsomed invested in XXX companies to date.
Ypsomed made its latest investment on XXXXXXXX, XXXXX. Ypsomed invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Ypsomed
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ypsomed
| When was Ypsomed founded? | Ypsomed was founded in 2003. |
| Where is Ypsomed headquartered? | Ypsomed is headquartered in Switzerland. |
| How many employees does Ypsomed have? | As of today, Ypsomed has over 2K employees. |
| Who is the CEO of Ypsomed? | Ypsomed's CEO is Simon Michel. |
| Is Ypsomed publicly listed? | Yes, Ypsomed is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of Ypsomed? | Ypsomed trades under YPSN ticker. |
| When did Ypsomed go public? | Ypsomed went public in 2004. |
| Who are competitors of Ypsomed? | Ypsomed main competitors are Snibe, Andon Health, APT Medical, Imeik Technology Development. |
| What is the current market cap of Ypsomed? | Ypsomed's current market cap is $5B. |
| What is the current revenue of Ypsomed? | Ypsomed's last 12 months revenue is $924M. |
| What is the current revenue growth of Ypsomed? | Ypsomed revenue growth (NTM/LTM) is (1%). |
| What is the current EV/Revenue multiple of Ypsomed? | Current revenue multiple of Ypsomed is 5.9x. |
| Is Ypsomed profitable? | Yes, Ypsomed is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ypsomed? | Ypsomed's last 12 months EBITDA is $421M. |
| What is Ypsomed's EBITDA margin? | Ypsomed's last 12 months EBITDA margin is 46%. |
| What is the current EV/EBITDA multiple of Ypsomed? | Current EBITDA multiple of Ypsomed is 13.1x. |
| What is the current FCF of Ypsomed? | Ypsomed's last 12 months FCF is $32M. |
| What is Ypsomed's FCF margin? | Ypsomed's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Ypsomed? | Current FCF multiple of Ypsomed is 172.6x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.